Demand for drug eruptions treatment will increase through 2036, with corticosteroids at 36.9% of the drug class segment in 2026. Oral administration leads the route of administration segment with a 44.7% share. The market is projected to reach USD 4.6 billion in 2026 and USD 8.62 billion by 2036.